Skip to main content

Anti-GARP Chimeric Antigen Receptor-T Cells

Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas

  • RegistryNCT06964737
  • PhasePhase 1
  • StatusRecruiting
  • ConditionRecurrent Malignant Glioma
  • SponsorOhio State University Comprehensive Cancer Center
How Anti-GARP Chimeric Antigen Receptor T Cel… worksNCT069647371 min

What the film says

Read the transcript

When a high-grade glioma returns after standard treatment, there is no agreed next step. And the tumor walls itself off, releasing a signal, TGF-beta, that tells immune cells to stand down.

The idea: go after the protein that holds that signal on the cell surface.

It is called GARP; tumors with a lot of it do worse. A patient's own T cells are fitted with a receptor for it. At surgery, a small reservoir is placed under the scalp, and over five weeks the cells go straight into the cavity the tumor left.

In mice, the cells worked against several glioblastoma models without serious harm. This trial, at Ohio State with Brad Elder, asks first whether it is safe. Public record; not medical advice.

Sources behind this film

The drug

What is being tested.

PRIMARY OBJECTIVE: I. To assess the safety and feasibility of a CAR T targeting GARP for glioma by defining rate, frequency, and severity of dose limiting toxicities (DLT) following intracavity administration to patients with recurrent glioma, to determine recommended phase II dose (RP2D). SECONDARY OBJECTIVES: I. To describe the adverse event profile of anti-GARP CAR T cell therapy. II.

To describe the cytokine levels and immunophenotype in cerebrospinal fluid (CSF) during and following anti-GARP CAR T cell therapy. III. To describe the duration of anti-GARP CAR T cell persistence and phenotype in CSF. IV. To describe anti-tumor activity of anti-GARP CAR T cell therapy based on objective response rate (ORR), as measured by established radiological criteria. V.

Giving anti-GARP CAR T cell therapy may be safe, tolerable, and/or effective in treating patients with recurrent grade III or IV gliomas.

The study

How the trial runs.

This phase I trial tests the safety, side effects, and best dose of anti-glycoprotein-A repetitions predominant (GARP) chimeric antigen receptor (CAR) T cell therapy and how well it works in treating patients with grade III or IV gliomas that have come back after a period of improvement (recurrent). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack tumor cells.

T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein, such as GARP, on the patient's tumor cells is added to the T cells in the laboratory. The special receptor is called a CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain tumors.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Patients are ≥ 18 years old
  • Capacity to understand and willingness to provide written informed consent
  • Diagnosis or clinical suspicion of recurrent malignant glioma, including:
  • History of high-grade glioma (World Health Organization [WHO] grade III or IV), or
  • Prior, histologically-confirmed diagnosis of grade II glioma with new radiographic findings consistent with a high-grade glioma
  • Imaging and/or histopathological confirmation of recurrent disease, or verification of "high risk" histology confirmed by a biopsy with measurable disease by the Radiologic Assessment in Neuro-Oncology (RANO) criteria

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.